Johnson & Johnson (JNJ:NYSE)
Snapshot of Johnson & Johnson (JNJ)
|
OPEN
$61.82
|
PREVIOUS CLOSE
$61.94
|
||
|
DAY HIGH
$62.62
|
DAY LOW
$61.72
|
||
|
52 WEEK HIGH
10/12/09 - $62.74
|
52 WEEK LOW
03/9/09 - $46.25
|
||
|
MARKET CAP
171.9B
|
AVERAGE VOLUME 3 mo
11.7M
|
||
|
DILUTED EPS TTM
$4.58
|
SHARES OUTSTANDING
2.8B
|
||
|
EX-DATE
11/20/09
|
P/E TTM
13.6x
|
||
|
DIVIDEND
$1.96
|
DIVIDEND YIELD
3.15%
|
||
| K = Thousands M = Millions B = Billions | |||
BUSINESS EXCHANGE RELATED TOPICJohnson & Johnson | |||
related business week news
Low-income kids can get experience and a degree in six years, with no debt and a job at the end, thanks to Workforce Outsource Services
Employers and hospitals don't have to wait for Congress to address inefficiencies and waste
Employers and hospitals don't have to wait for Congress to address inefficiencies and waste
Following its settlement of kickback allegations with Omnicare, the Justice Dept. continues to probe Johnson & Johnson
related news
JNJ Details
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSON’S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names. The company’s Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology, and virology. Its products include REMICADE, a biologic to treat Crohn’s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, as well as for treating migraines; PROCRIT that stimulates red blood cell production; RISPERDAL oral, a medication to treat the symptoms of schizophrenia, bipolar mania, and irritability associated with autistic behavior in indicated patients; RISPERDAL CONSTA, an injectable, and INVEGATM Extended-Release tablets to treat schizophrenia; LEVAQUIN and FLOXIN, anti-infective products; CONCERTA, a product for treating attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain. Johnson & Johnson’s Medical Devices and Diagnostics segment offers circulatory disease management, orthopaedic joint reconstruction and spinal care and sports medicine, surgical care and women’s health, minimally invasive surgical, blood glucose monitoring and insulin delivery, and diagnostic products, as well as disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey.
JNJ Top Compensated Officers
Key developments for Johnson & Johnson (JNJ)
Johnson & Johnson - Conference Presentation Calls
Johnson & Johnson closed down ColBar, an Israeli start-up that it acquired in late 2006 for $159 million. The remaining employees were let go. Johnson & Johnson tried to sell the company for $20-40 million in recent months, and was apparently willing to settle for even less, but to no avail. Efforts are still underway to sell ColBar's facilities, in which $10 million were invested. The closure was probably due to a mix of marketing and operational problems.
Johnson & Johnson expected to Report Fiscal Year 2009 Results on January 26, 2010. This event was calculated by Capital IQ (Created on November 4, 2009).
BusinessWeek Rankings
Stock Quotes
| Recently Viewed | |||
| JNJ | $62.31 USD | +0.37 |  |
|---|---|---|---|
| T | $26.02 USD | -0.09 |  |
| GE | $15.59 USD | -0.17 |  |
| MSFT | $29.62 USD | -0.16 |  |
Market data is delayed at least 20 minutes.
JNJ Competitors
| Company | Last | Change |
| Archer Daniels Midland Co | $31.62 USD | +0.05 |
| NOKIA | €8.96 EUR | -0.14 |
| Pfizer Inc | $18.36 USD | +0.25 |
| Toshiba Corporation | ¥451.00 JPY | -10.00 |
| Unilever | €20.72 EUR | +0.055 |
| View Industry Companies | ||
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | JNJ | Industry Range |
| Price/Earnings | 13.6x |
|
| Price/Sales | 2.8x |
|
| Price/Book | 3.4x |
|
| Price/Cash Flow | 13.5x |
|
| TEV/Sales | 2.4x |
|
|
JNJ |
||
JNJ transactions
| Type Date |
Target |
|
Merger/Acquisition
October 7, 2009 |
Johnson & Johnson, JONTEX |
|
Private Placement
July 2, 2009 |
Elan Corp. plc |
|
Merger/Acquisition
July 2, 2009 |
Alzheimer's Immunotherapy Program |
Companies Toolbox
Update/report
Submit private company
Upload your company video
Newsletter
Blogs
RSS feeds
Podcasts
VideosSEARCH FOR JOBS
Post a Job- Skillman, NJ-Johnson & Johnson Services
- Guaynabo, PR-Johnson & Johnson
- Tampa, FL-Johnson & Johnson
- Diamond Bar, CA-Johnson & Johnson
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For Johnson & Johnson (JNJ) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
